Small peptide inhibitor of JNK3 protects dopaminergic neurons from MPTP induced injury via inhibiting the ASK1-JNK3 signaling pathway

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Pan, Jing ^a   Li, Hui ^a   Zhang, Bei ^a   Xiong, Ran ^a   Zhang, Yu ^a   Kang, Wen Yan ^a   Chen, Wei ^a   Zhao, Zong Bo ^a   Chen, Sheng Di ^a,b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; APOPTOSIS SIGNAL REGULATING KINASE 1; BETA ARRESTIN 2; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE 12 N TAT; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; BETA ARRESTIN; MITOGEN ACTIVATED PROTEIN KINASE 10; PEPTIDE; PROTEIN KINASE INHIBITOR; RETINA S ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MITOCHONDRION; MOUSE; NERVE CELL NECROSIS; NONHUMAN; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; ARRESTINS; BETA-ARRESTINS; CELL LINE, TUMOR; CYTOPROTECTION; DOPAMINERGIC NEURONS; HUMANS; MALE; MAP KINASE KINASE KINASE 5; MICE; MICE, INBRED C57BL; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASE 10; MOLECULAR SEQUENCE DATA; PARKINSON DISEASE; PEPTIDES; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION;

EID: 84929494426     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119204     Document Type: Article

References (34)

1. de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Fratiglioni L, et al. (2000) Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54: 21-23. PMID: 10854357.
2. Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H (2002) Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 61: 413-426. PMID: 12030260.
3. Pan J, Xiao Q, Sheng CY, Hong Z, Yang HQ, Wang G, et al. (2009) Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease. Neurochem Int 54: 418-425. doi:10.1016/j.neuint.2009.01.013 PMID: 19428783.
4. Choi WS, Abel G, Klintworth H, Flavell RA, Xia Z (2010) JNK3 mediates paraquat- and rotenone-induced dopaminergic neuron death. J Neuropathol Exp Neurol 69: 511-520. doi:10.1097/NEN.0b013e3181db8100 PMID: 20418776.
5. Resnick L, Fennell M (2004) Targeting JNK3 for the treatment of neurodegenerative disorders. Drug Discov Today 9: 932-939. PMID: 15501728.
6. Kuan CY, Yang DD, Samanta Roy DR, Davis RJ, Rakic P, Flavell RA. (1999) The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 22: 667-676. PMID: 10230788.
7. Martin JH, Mohit AA, Miller CA (1996) Developmental expression in the mouse nervous system of the p493F12 SAP kinase. Brain Res Mol Brain Res 35: 47-57. PMID: 8717339.
8. Nagai H, Noguchi T, Takeda K, Ichijo H (2007) Pathophysiological roles of ASK1-MAP kinase signaling pathways. J Biochem Mol Biol 40: 1-6. PMID: 17244475.
9. Whitmarsh AJ, Davis RJ (1996) Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med (Berl) 74: 589-607. PMID: 8912180.
10. Song X, Coffa S, Fu H, Gurevich VV (2009) How does arrestin assemble MAPKs into a signaling complex? J Biol Chem 284: 685-695. doi:10.1074/jbc.M806124200 PMID: 19001375.
11. Li X, MacLeod R, Dunlop AJ, Edwards HV, Advant N, Gibson LC, et al. (2009) A scanning peptide array approach uncovers association sites within the JNK/beta arrestin signalling complex. FEBS Lett 583: 3310-3316. doi:10.1016/j.febslet.2009.09.035 PMID: 19782076.
12. Guo C, Whitmarsh AJ (2008) The beta-arrestin-2 scaffold protein promotes c-Jun N-terminal kinase-3 activation by binding to its nonconserved N terminus. J Biol Chem 283: 15903-15911. doi:10.1074/jbc.M710006200PMID: 18408005.
13. Xie X, Gu Y, Fox T, Coll JT, Fleming MA, Markland W, et al. (1998) Crystal structure of JNK3: A kinase implicated in neuronal apoptosis. Structure 6: 983-991. PMID: 9739089.
14. Wang Z, Liu J, Chen S, Wang Y, Cao L, Zhang Y, et al. (2011) DJ-1 modulates the expression of Cu/Zn-superoxide dismutase-1 through the Erk1/2-Elk1 pathway in neuroprotection. Ann Neurol 70: 591- 599. doi:10.1002/ana.22514 PMID: 21796667.
15. Furuya T, Hayakawa H, Yamada M, Yoshimi K, Hisahara S, Miura M, et al. (2004) Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci 24: 1865-1872. PMID: 14985426.
16. Mandir AS, Przedborski S, Jackson-Lewis V, Wang ZQ, Simbulan-Rosenthal CM, Smulson ME, et al. (1999) Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci U S A 96: 5774-5779. PMID: 10318960.
17. Ouyang M, Shen X (2006) Critical role of ASK1 in the 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells. J Neurochem 97: 234-244. PMID: 16515547.
18. Liedhegner EA, Steller KM, Mieyal JJ (2011) Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson's disease. Chem Res Toxicol 24: 1644-1652. doi:10.1021/tx200082h PMID: 21815648.
19. Kuan CY, Whitmarsh AJ, Yang DD, Liao G, Schloemer AJ, Dong C, et al. (2003) A critical role of neural- specific JNK3 for ischemic apoptosis. Proc Natl Acad Sci U S A 100: 15184-15189. PMID: 14657393.
20. Yang DD, Kuan CY, Whitmarsh AJ, Rincon M, Zheng TS, Davis RJ, et al. (1997) Absence of excitotoxicity- induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 389: 865-870. PMID: 9349820.
21. Morishima Y, Gotoh Y, Zieg J, Barrett T, Takano H, Flavell R, et al. (2001) Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci 21: 7551-7560. PMID: 11567045.
22. Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, Przedborski S, et al. (2004) JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 101: 665-670. PMID: 14704277.
23. Brecht S, Kirchhof R, Chromik A, Willesen M, Nicolaus T, Raivich G, et al. (2005) Specific pathophysiological functions of JNK isoforms in the brain. Eur J Neurosci 21: 363-377. PMID: 15673436.
24. Ries V, Silva RM, Oo TF, Cheng HC, Rzhetskaya M, Kholodilov N, et al. (2008) JNK2 and JNK3 combined are essential for apoptosis in dopamine neurons of the substantia nigra, but are not required for axon degeneration. J Neurochem 107: 1578-1588. doi:10.1111/j.1471-4159.2008.05713.x PMID: 19014392.
25. Antoniou X, Falconi M, Di Marino, D, Borsello T (2011) JNK3 as a therapeutic target for neurodegenerative diseases. J Alzheimers Dis 24: 633-642. doi:10.3233/JAD-2011-091567 PMID: 21321401.
26. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, et al. (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 98: 13681-13686. PMID: 11717429.
27. Wang W, Shi L, Xie Y, Ma C, Li W, Su X, et al. (2004) SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease. Neurosci Res 48: 195-202. PMID: 14741394.
28. Kuan CY, Burke RE (2005) Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy. Curr Drug Targets CNS Neurol Disord 4: 63-67. PMID: 15723614.
29. Borsello T, Forloni G (2007) JNK signalling: A possible target to prevent neurodegeneration. Curr Pharm Des 13: 1875-1886. PMID: 17584114.
30. Saporito MS, Brown EM, Miller MS, Carswell S (1999) CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. J Pharmacol Exp Ther 288: 421-427. PMID: 9918541.
31. Wang LH, Johnson EM Jr. (2008) Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 71: 462; author reply 462-463. doi:10.1212/01.wnl.0000324506. 93877.5e PMID: 18678833.
32. Cheng HC, lane CM, Burke RE.(2010) Clinical progression in Parkinson disease and the neurobiology of axons Ann Neurol.715-25.
33. Hess J, Angel P, Schorpp-Kistner M. (2004) AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117:5965-73. PMID: 15564374.
34. Ameyar M, Wisniewska M, Weitzman JB. (2003) A role for AP-1 in apoptosis: The case for and against. Biochimie 85:747-52. PMID: 14585541.